Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 401

Sort by

Sort Order Select

Journal Articles

Selective Targeting of Histone Deacetylase 11 Disables Metabolism of Myeloproliferative Neoplasms

Blood (2019) 134 (Supplement_1): 474.

https://doi.org/10.1182/blood-2019-127235

Published: 2019

Journal Articles

The IMiD-Target Cereblon Determines Transmembrane Protein Quality Control Promoting Tumor Metabolism

Michael Heider, Ruth Eichner, Jacob Stroh, Anna Kuisl, Jana Zecha, Jannis Lawatscheck, Martina Rudelius, Anne-Kathrin Garz, Simone Lemeer, Christian Peschel, Ulrich Keller, MD, Katharina Götze, Johannes Buchner, Bernhard Kuster, Vanesa Fernandez-Saiz, Florian Bassermann, MD PhD

Blood (2019) 134 (Supplement_1): 314.

https://doi.org/10.1182/blood-2019-129064

Published: 2019

Journal Articles

Mebendazole Mediates Its Anti-Leukemic Effects By Proteasomal Degradation of GLI Transcription Factors Via Inhibition of HSP70/90-Chaperone Activity in Acute Myeloid Leukemia in a Preclinical and Clinical Setting

Fabian Freisleben, Hauke Stamm, PhD, Jana Muschhammer, Vanessa Thaden, Franziska Modemann, MD, Alexander Krispien, Franziska Brauneck, Jasmin Wellbrock, PhD, Walter Fiedler, MD

Blood (2019) 134 (Supplement_1): 5050.

https://doi.org/10.1182/blood-2019-129973

Published: 2019

Journal Articles

In silico Prediction Followed By in Vitro validation Identifies the Survivin Inhibitor YM155 As a Potent Secondary Drug Against Pi-Resistant Myeloma

Harish Kumar, PhD, Ujjal Kumar Mukherjee, PhD, Li Chen, PhD, Amit Kumar Mitra, PhD MSc, BSc

Blood (2019) 134 (Supplement_1): 5543.

https://doi.org/10.1182/blood-2019-131923

Published: 2019

Journal Articles

Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis

Naveen Pemmaraju, MD, Krishna Gundabolu, MBBS, Kristen Pettit, MD, Moshe Talpaz, MD, Nikolai A. Podoltsev, MD PhD, Gary J. Schiller, MD, Peter Eisenberg, MD, Hagop Youssoufian, MD, Susan Duggan, RN, MBA, Barbara Wallner, PhD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 4178.

https://doi.org/10.1182/blood-2019-130310

Published: 2019

Journal Articles

LAM-003, a Novel Oral Heat Shock Protein 90 Inhibitor for Treatment of Acute Myeloid Leukemia, Including Wild-Type and FMS-like Tyrosine Kinase 3 (FLT3)-Mutant Disease

Neil Beeharry, Sean Landrette, PhD, Jeff Grotzke, PhD, Sophia Gayle, PhD, Marylens Hernandez, PhD, Stephanie Halene, MD, Peter R Young, PhD, Langdon L Miller, MD, Tian Xu, PhD, Jonathan Rothberg, PhD, Henri Lichenstein, PhD

Blood (2019) 134 (Supplement_1): 2664.

https://doi.org/10.1182/blood-2019-125770

Published: 2019

Journal Articles

Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia

Michael Broux, Cristina Prieto, Sofie Demeyer, Marlies Vanden Bempt, Llucia Alberti-Servera, Inge Lodewijckx, Roel Vandepoel, Nicole Mentens, Olga Gielen, Kris Jacobs, Ellen Geerdens, Carmen Vicente, Charles E. de Bock, Jan Cools

Blood (2019) 134 (16): 1323–1336.

https://doi.org/10.1182/blood.2019000015

Published: 2019

Includes: Supplemental data

Journal Articles

PRC2 Inactivation Induces Resistance to Chemotherapy-Induced Apoptosis By Upregulating the TRAP1 Mitochondrial Chaperone in T-ALL

Blood (2018) 132 (Supplement 1): 889.

https://doi.org/10.1182/blood-2018-99-113518

Published: 2018

Journal Articles

Targeting BCL-2, BCL-XL, BCL-W and MDM2 in B-Cell Acute Lymphoblastic Leukemia Is Highly Effective Ex Vivo

Helena Hohtari, MD, Shady Awad, MD, Olli Dufva, Swapnil Potdar, MSc, Caroline A Heckman, PhD, Krister Wennerberg, PhD, Satu Mustjoki, MD PhD, Kimmo Porkka, MD PhD

Blood (2018) 132 (Supplement 1): 3975.

https://doi.org/10.1182/blood-2018-99-110610

Published: 2018

Journal Articles

Significant In Vivo Sensitivity to Aurora Kinase Inhibition in TCF3-Hlf rearranged Acute Lymphoblastic Leukemia

Bill H. Chang, MD PhD, Jessica Leonard, MD, Joelle Wolf, Michelle Degnin, BS, Kyle Lenz, MD, Beth Wilmot, PhD, Charles G. Mullighan, MBBS, MD, Mignon L. Loh, MD, Stephen P. Hunger, MD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD

Blood (2018) 132 (Supplement 1): 4026.

https://doi.org/10.1182/blood-2018-99-115706

Published: 2018

Journal Articles

Using HSP90 Inhibitors to Target DNA Repair Proteins in AML

Janani Ravikrishnan, BS, Tzung-Huei Lai, PhD, Shaneice Renee Mitchell, BS, Pei-Jung Wu, BS, Shelley Orwick, BS, Chaomei Liu, PhD, Jennifer A. Woyach, MD, Alice S. Mims, MD, William Plunkett, PhD, Vinay K Puduvalli, MD MBBS, John C. Byrd, MD, Rosa Lapalombella, PhD, Deepa Sampath, PhD

Blood (2018) 132 (Supplement 1): 5144.

https://doi.org/10.1182/blood-2018-99-116485

Published: 2018

Journal Articles

Drug Combinations Co-Targeting Myeloid Cell Leukemia-1 (Mcl-1) Protein Can Overcome Microenvironmentally-Induced Multi-Drug Tolerance in Non-Hodgkin Lymphomas

Kallesh D. Jayappa, DVM, PhD, Craig A. Portell, MD, Vicki L. Gordon, BSc, Goutham Narla, MD PhD, Timothy P. Bender, PhD, Michael E. Williams, MD, Michael J. Weber, PhD

Blood (2018) 132 (Supplement 1): 2649.

https://doi.org/10.1182/blood-2018-99-116759

Published: 2018

Journal Articles

Novel Allosteric Inhibitors of Heat Shock Protein 70 As Agents to Probe Protein Homeostasis and Overcome Proteasome Inhibitor Resistance in Multiple Myeloma

Ian Ferguson, BA, Christine Lam, BA, Margarette C. Mariano, MS, Donghui Wang, BA, Paul Phojanakong, BA, Sami Toumivaara, PhD, Hao Shao, PhD, Byron C Hann, MD PhD, Jason Gestwicki, PhD, Arun P Wiita, MDPhD

Blood (2018) 132 (Supplement 1): 3212.

https://doi.org/10.1182/blood-2018-99-117401

Published: 2018

Journal Articles

Calcium/Calmodulin Dependent Protein Kinase 2 Gamma Is Identified As a Potential Therapeutic Target of Myelofibrosis Using Disease-Specific Induced Pluripotent Stem Cells

Masashi Miyauchi, MD PhD, Ken Sasaki, MD, Kazuki Taoka, MD PhD, Yosuke Masamoto, MD PhD, Sho Yamazaki, MD PhD, Shunya Arai, MD PhD, Mineo Kurokawa, MD PhD

Blood (2018) 132 (Supplement 1): 3054.

https://doi.org/10.1182/blood-2018-99-113285

Published: 2018

Journal Articles

SE-7552, a Highly Selective, Non-Hydroxamate Inhibitor of Histone Deacetylase-6 Blocks Multiple Myeloma Growth In Vivo

Jason A Holt, MSc, Edward P Garvey, PhD, J. David Becherer, PhD, William J Hoekstra, PhD, Robert J Schotzinger, MD PhD, Christopher M Yates, MSc

Blood (2018) 132 (Supplement 1): 3215.

https://doi.org/10.1182/blood-2018-99-113066

Published: 2018

Journal Articles

Therapeutic Targeting of HSP90 in AML and ALL

Sanil Bhatia, PhD, Heinz Ahlert, Msc, Benedikt Frieg, PhD, Arndt Borkhardt, MD, Holger Gohlke, PhD, Thomas Kurz, Julia Hauer, MD

Blood (2018) 132 (Supplement 1): 4680.

https://doi.org/10.1182/blood-2018-99-120362

Published: 2018

Journal Articles

Long Non-Coding RNA NEAT1 Is Upregulated By Heat Shock Factor 1 (HSF1) and Associated with Multiple Myeloma Progression

Blood (2018) 132 (Supplement 1): 1904.

https://doi.org/10.1182/blood-2018-99-113720

Published: 2018

Journal Articles

HSP90 inhibition without heat shock response

John C. Byrd

Blood (2018) 132 (3): 241–242.

https://doi.org/10.1182/blood-2018-05-850271

Published: 2018

Journal Articles

Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response

Blood (2018) 132 (3): 307–320.

https://doi.org/10.1182/blood-2017-10-810986

Published: 2018

Includes: Supplemental data

Journal Articles

A Decade of Drug Development through Phase-1 Trials; Systematic Review of Literature for Novel Drugs and Targets in Multiple Myeloma

Imad Ud Deen, MBBS, Muhammad Umar Khalid, MD, Atlantis Dawn Russ, MD PhD, Anh Hua, BS, Ahmad Iftikhar, MD, Adeela Mushtaq, MD, Ahmad Safdar, BS, Ali McBride, PharmD,MS, Faiz Anwer, MD

Blood (2017) 130 (Supplement 1): 5399.

https://doi.org/10.1182/blood.V130.Suppl_1.5399.5399

Published: 2017

NARROW

Selective Targeting of Histone Deacetylase 11 Disables Metabolism of Myeloproliferative Neoplasms

The IMiD-Target Cereblon Determines Transmembrane Protein Quality Control Promoting Tumor Metabolism

Mebendazole Mediates Its Anti-Leukemic Effects By Proteasomal Degradation of GLI Transcription Factors Via Inhibition of HSP70/90-Chaperone Activity in Acute Myeloid Leukemia in a Preclinical and Clinical Setting

In silico Prediction Followed By in Vitro validation Identifies the Survivin Inhibitor YM155 As a Potent Secondary Drug Against Pi-Resistant Myeloma

Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis

LAM-003, a Novel Oral Heat Shock Protein 90 Inhibitor for Treatment of Acute Myeloid Leukemia, Including Wild-Type and FMS-like Tyrosine Kinase 3 (FLT3)-Mutant Disease

Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia

PRC2 Inactivation Induces Resistance to Chemotherapy-Induced Apoptosis By Upregulating the TRAP1 Mitochondrial Chaperone in T-ALL

Targeting BCL-2, BCL-XL, BCL-W and MDM2 in B-Cell Acute Lymphoblastic Leukemia Is Highly Effective Ex Vivo

Significant In Vivo Sensitivity to Aurora Kinase Inhibition in TCF3-Hlf rearranged Acute Lymphoblastic Leukemia

Using HSP90 Inhibitors to Target DNA Repair Proteins in AML

Drug Combinations Co-Targeting Myeloid Cell Leukemia-1 (Mcl-1) Protein Can Overcome Microenvironmentally-Induced Multi-Drug Tolerance in Non-Hodgkin Lymphomas

Novel Allosteric Inhibitors of Heat Shock Protein 70 As Agents to Probe Protein Homeostasis and Overcome Proteasome Inhibitor Resistance in Multiple Myeloma

Calcium/Calmodulin Dependent Protein Kinase 2 Gamma Is Identified As a Potential Therapeutic Target of Myelofibrosis Using Disease-Specific Induced Pluripotent Stem Cells

SE-7552, a Highly Selective, Non-Hydroxamate Inhibitor of Histone Deacetylase-6 Blocks Multiple Myeloma Growth In Vivo

Therapeutic Targeting of HSP90 in AML and ALL

Long Non-Coding RNA NEAT1 Is Upregulated By Heat Shock Factor 1 (HSF1) and Associated with Multiple Myeloma Progression

HSP90 inhibition without heat shock response

Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response

A Decade of Drug Development through Phase-1 Trials; Systematic Review of Literature for Novel Drugs and Targets in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only